Hanger Orthopedic Group Announces Preliminary Third Quarter Revenue an... (and third party patient care centers. Th...)

Hanger Orthopedic Group Announces Preliminary Third Quarter Revenue and Earnings

Date:10/18/2010

and third party patient care centers. The third is Linkia, which is the first and only provider network management company for the orthotics and prosthetics industry. The fourth unit, Innovative Neurotronics, introduces emerging neuromuscular technologies developed through independent research in a collaborative effort with industry suppliers worldwide. For more information on Innovative Neurotronics, Inc. or the WalkAide®, visit http://www.ininc.us. For more information on Hanger, visit http://www.hanger.com.

This document contains forward-looking statements relating to the Company's results of operations. The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. Statements relating to future results of operations in this document reflect the current views of management. However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products and the other factors identified in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Management relies on the non-GAAP items as the primary measures to review and assess operating performance and management teams. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. Management and investors also revi
'/>"/>

SOURCE Hanger Orthopedic Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
2. Hanger Orthopedic Group, Inc. Announces Third Quarter 2010 Earnings Release Conference Call
3. Hanger Orthopedic Group, Inc. Announces Second Quarter 2010 Earnings Release Conference Call
4. Hanger Ivan R. Sabel Foundation to Receive $75,000 Donation Towards Charitable Prosthetic Efforts in Haiti from Grapes for Humanity/US
5. Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction
6. Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million
7. Hanger Orthopedic Group, Inc. Reports an Increase of 42.3% in Earnings Per Share, to $0.37 on a 10.6% Sales Increase, for the Fourth Quarter 2009
8. Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call
9. Hanger Orthopedic Group Increases Q4 2009 Sales and EPS Guidance
10. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling $10.7 Million of Annual Net Revenue
11. Orthopedics This Week Announces 2010 Best Spine Technology Award Winners

Post Your Comments:

(Date:5/21/2013)... 2013 Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, municipalities, healthcare and first ... today announced that the Company accepted a commitment ... Facility subject to certain terms and conditions and ... no assurances can be given that this transaction ...

(Date:5/21/2013)... 21, 2013 Tom Daulton, CEO of Mammotome, a division ... Year by the Cincinnati chapter of ... by another local top executive who is also a breast ... Ethicon Endo-Surgery in March of 2010. Daulton will be presented ... presented by Huntington Bank, on May 22. The ...

(Date:5/21/2013)... Kepner-Tregoe (KT), the global capability development ... Chris Geraghty has been ... than 20 years serving the industrial sector, holding ... succeeds Ray Baxter , who ... the Board and CEO. (Logo: ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... 14, 2011 /PRNewswire / -- Nephros, Inc. (OTC Bulletin Board: ... three months ended September 30, 2011. Recent ... associated with Rights Offering to be exercised; Received initial ... Hemodiafiltration System in U.S. Financial ...

... 14, 2011 Landauer, Inc. (NYSE: LDR ... radiation monitoring and the leading domestic provider of outsourced ... all of the outstanding equity interests of IZI Medical ... a purchase price of approximately $93 million. IZI Medical ...

Cached Medicine Technology:Nephros Reports Third Quarter 2011 Financial Results 2 Nephros Reports Third Quarter 2011 Financial Results 3 Nephros Reports Third Quarter 2011 Financial Results 4 Nephros Reports Third Quarter 2011 Financial Results 5 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 2 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 3 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 4 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 5 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 6

Nephros Reports Third Quarter 2011 Financial Results Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...

(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...

(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...

(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...

(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Researchers find genetic risk factor for pulmonary fibrosis

... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...

... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...

... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...

... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...

... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...

... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...

Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5 Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4 Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4 Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2

Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment CareFusion Announces Board of Directors, Progress on Alaris Consent Decree United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

Medicine Products:

4V63 4V61-R 4V42-R 4V58-R